Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782470 · ClinicalTrials.gov registry record
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 38
- Enrollment target
NCT00782470: Completed study, sponsored by Bayer.
NCT00782470 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00782470 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity level and reasons that might influence the desire to switch.
Interventions
- BEHAVIORAL Recombinant Factor VIII (Kogenate, BAY 14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-11 |
What the finished NCT00782470 record still lists
NCT00782470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Factor VIII (Kogenate, BAY 14-2222) is the first listed.
NCT00782470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00782470 about?
NCT00782470 is a clinical study titled "Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A". Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity le...
What is the current status of trial NCT00782470?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2007-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00782470?
The interventions under investigation include: Recombinant Factor VIII (Kogenate, BAY 14-2222) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00782470?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia